Description
Description
This page contains brief details about the drug trastuzumab deruxtecan, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
| ENHERTU PWD 100MG | VIAL | 142000 | 167069 |
Date of Approval
Trastuzumab deruxetecan was first approved by the United States Food and Drug Administration (FDA) on December 20, 2019.
In a 2021 study, researchers assessed the safety and activity of trastuzumab deruxtecan (T-DXd) in patients with various HER2-expressing or HER2-mutant solid tumours. They reported a confirmed objective response rate (ORR) of 28.3% and a median progression-free survival (PFS) of 7.2 months.
The study highlighted promising activity in HER2-mutant non-small cell lung cancer (NSCLC) and other solid tumours.
Mechanism of Action of Trastuzumab Deruxtecan
Trastuzumab deruxetecan is an antibody-drug conjugate that targets HER2. It uses a humanised anti-HER2 IgG1 antibody. Trastuzumab deruxetecan includes a small molecule called DXd, which inhibits topoisomerase I and is linked to the antibody by a cleavable connector.
Once it binds to HER2 on cancer cells, Trastuzumab deruxetecan is taken into the cell. Inside the cell, the linker is broken down by lysosomal enzymes, releasing DXd. This molecule then causes DNA damage and triggers cell death.
Uses of Trastuzumab Deruxtecan
Trastuzumab deruxetecan is used in the treatment of the following:
HER2-positive metastatic breast cancer: Treat adult patients with inoperable or metastatic HER2-positive breast cancer who have already received a prior anti-HER2-based treatment.
HER2-low metastatic breast cancer: Treat adult patients with inoperable or metastatic HER2-low breast cancer who have undergone prior chemotherapy in the metastatic setting or experienced cancer recurrence during or within six months of completing adjuvant chemotherapy.
Locally advanced or metastatic gastric cancer: Treat adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have already received a prior trastuzumab-based treatment.
Trastuzumab Deruxtecan Dosage available
Trastuzumab deruxtecan is available as an injection and administered intravenously (into a vein) by the healthcare provider on scheduled appointments. Your healthcare provider will decide the suitable dosage for your condition according to your age and physical circumstances.
